Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00105105 · ClinicalTrials.gov registry record · Phase 2
Mifepristone as Adjunctive Therapy in Alzheimer's Disease
A Phase 2 study, sponsored by Corcept Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT00105105 is a Phase 2 study that was terminated before completion, run by Corcept Therapeutics. The registered enrollment target is 160 participants.
The verdict
NCT00105105, a Phase 2 study, was terminated before completion, sponsored by Corcept Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of C-1073 (Mifepristone) on cognition in patients with Alzheimer's disease (AD) who are also taking an acetylcholinesterase inhibitor (Aricept, Exelon or Reminyl).
Interventions
- DRUG Mifepristone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2003-04 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00105105
The ClinicalTrials.gov registry entry for NCT00105105 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mifepristone is the first listed.
NCT00105105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00105105 about?
NCT00105105 is a clinical study titled "Mifepristone as Adjunctive Therapy in Alzheimer's Disease". The purpose of this study is to evaluate the effects of C-1073 (Mifepristone) on cognition in patients with Alzheimer's disease (AD) who are also taking an acetylcholinesterase inhibitor (Aricept, Exelon or Reminyl).
What is the current status of trial NCT00105105?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2003-04. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00105105?
The interventions under investigation include: Mifepristone (DRUG).
Who is sponsoring clinical trial NCT00105105?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.